<< Back

Jaguar Animal Health Names VP, Commercial Operations

09:38 AM Eastern Daylight Time

SAN FRANCISCO--(BUSINESS WIRE)--Jaguar Animal Health, Inc., (“Jaguar” or the “Company”) an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, today named Ian Parker, a seasoned executive who has spent 30 years in the animal health industry, Vice President, Commercial Operations.

Parker joins Jaguar from Bioniche Animal Health, where he headed sales and marketing for the company’s US subsidiary. He began his career in the UK with Glaxo Animal Health and subsequently spent time in Europe prior to moving to the US with SmithKline Animal Health. Parker has had direct product launch experience in companion animals, equine and cattle, in both Europe and the US. He has also held management positions at Norden Europe, a division of SmithKline Animal Health, Nutramax Laboratories, Vetoquinol, Smartpak Equine and CDA Veterinary and PD Sales Associates.

According to Chief Executive Officer, Lisa Conte, “Ian will play a major role in our planned commercial launches of Jaguar’s first non-prescription product later this year and our first prescription product launch targeted for early 2016. Ian brings to the team a track record in not only domestic and international animal health product sales and marketing but also entrepreneurial companies and big pharma. Having begun his career as a product manager, he has led multiple organizations’ strategic direction and management of product introductions as well as broad-based marketing programs. His expertise extends across prescription and non-prescription products, and his experience complements the resident expertise at Jaguar.“


Jaguar Animal Health, Inc. is an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals. Canalevia™ is the Company’s lead prescription drug product candidate for the treatment of various forms of watery diarrhea in dogs. Neonorm™ is the company’s lead non-prescription product to address the symptoms of watery diarrhea, or scours, in preweaned dairy calves, for which a commercial launch is planned in the United States by the end of 2014. Canalevia™ is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree. Neonorm is a botanical extract derived from the Croton lechleri tree. Canalevia and Neonorm are distinct products that act at the same last step in a physiological pathway generally present in mammals. Jaguar has six investigational new animal drug applications, or INADs, on file with the FDA and intends to develop species-specific formulations of Neonorm in six additional target species. For more information, please visit www.jaguaranimalhealth.com


for Jaguar Animal Health, Inc.
Shari Annes, 650-888-0902
Investor Relations